Flecainide acetate is indicated for use in patients with the following arrhythmias: Severe symptomatic supraventricular arrhythmia AV nodal reciprocating tachycardia. Arrhythmias associated with the Wolff-Parkinson-White syndrome and similar conditions associated with the presence of accessory pathways. Paroxysmal atrial fibrillation in patients with disabling symptoms after cardioversion. Patients with structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk of pro-arrhythmic effects. Arrhythmias of recent onset will respond more readily. Symptomatic sustained ventricular tachycardia. Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms which have failed to respond to other forms of therapy or in which other treatments have not been tolerated. Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.